retatrutide trial results phase 2 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people The numbers from Lilly's Phase

Quick answer: In the Phase 2 clinical trial (Jastreboff et al., 2023, New England Journal of Medicine ), retatrutide was given by once-weekly subcutaneous injection across a 112mg range

A lactulose breath test can diagnose the condition, and treatment typically involves a course of antibiotics like rifaximin

What may change after approval If retatrutide reaches FDA approval, the pricing conversation could shift from a patchwork of self-pay options toward a more familiar system

The company projects non-GAAP EPS of $33.50 to $35.00, above the $33.04 consensus

According to clinical trials, its use can provide significant advantages to people suffering from obesity or excess weight, particularly anyone who might not have had success with other therapies

It is essential to emphasise that chemical degradation may occur without any visible change to the solution